New development in the COPD drug Indaceterol

The patented COPD drug Indaceterol is imported by Novartis and sold under an agreement by Lupin at a price of Rs. 677 for a unit of ten capsules whereas Cipla’s in October 2014 launched at risk the generic version at Rs.130 for a unit of 10 capsules. 

Cipla’s petition to the Department of Industrial Policy & Promotion (DIPP) to revoke the Novartis patents on Indaceterol is available here

In a new development, Novartis filed a trademark infringement case against Cipla in the Delhi High Court on the ground that Cipla’s brandname UNIBREZ – for Indaceterol – was confusingly similar to its brandname Onbrez. The matter – NOVARTIS A.G., AND ANR Vs. CIPLA LTD, CS(OS) 3356/2014 – was heard and dismissed on 17th November 2014 as Cipla agreed to amend its brandname.

This entry was posted in Pricing and tagged , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s